ACEi/ARBs, Drugs Monitor

(25 Feb 2021) ACEI/ARB- showed a beneficial effect on mortality

March 1, 2021

Effect of in-hospital treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on mortality and complications in patients hospitalized for COVID-19: a large Spanish cohort study https://www.medrxiv.org/content/10.1101/2021.02.24.21252391v1 Between February and June 2020, 11,205 patients were included, with mean age… Continue reading "(25 Feb 2021) ACEI/ARB- showed a beneficial effect on mortality"

(25 Nov 2020) ACE-I/ARB therapy – mortality is not associated with ACE-I/ARB therapy

November 27, 2020

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study https://doi.org/10.1177/1074248420976279 This multi-center, prospective study ( NCT4357535) enrolled patients hospitalized for COVID-19 and receiving one or more antihypertensive agents to manage either hypertension… Continue reading "(25 Nov 2020) ACE-I/ARB therapy – mortality is not associated with ACE-I/ARB therapy"

(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension.

July 23, 2020

Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID‐19 patients with hypertension in Wuhan: A hospital‐based retrospective cohort study https://doi.org/10.1002/jmv.26315 This retrospective single-center case series analyzed COVID-19 patients with hypertension, treated with ACEIs/ACEIs or CCBs . After PSM analysis,… Continue reading "(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension."

Tag: ACEi/ARBs

(25 Feb 2021) ACEI/ARB- showed a beneficial effect on mortality

(25 Nov 2020) ACE-I/ARB therapy – mortality is not associated with ACE-I/ARB therapy

(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension.